Hypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosis

Psychoneuroendocrinology

Volumn 45, Issue , 2014, Pages 87-95

  Kümpfel, Tania ^a,b   Schwan, Michaela ^a,c   Weber, Frank ^a   Holsboer, Florian ^a   Trenkwalder, Claudia ^a,d   Then Bergh, Florian ^a,e  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Praxisgemeinschaft Karlbauer   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Hypothalamo pituitary adrenal axis; Multiple sclerosis; Neuroendocrinology

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GLATIRAMER; HYDROCORTISONE; METHYLPREDNISOLONE; STEROID;

ADRENAL HYPERPLASIA; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; CLINICAL TRIAL; DIAGNOSTIC USE; ENDOCRINE SYSTEM EXAMINATION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LONGITUDINAL STUDY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; CORTICOTROPIN-RELEASING HORMONE; DEXAMETHASONE; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; PITUITARY-ADRENAL SYSTEM;

EID: 84901218493     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.03.012     Document Type: Article

References (26)

1. Compston A., Confavreux C., Lassmann H., McDonald I., Miller D., Noseworthy J.H., Smith K., Wekerle H. McAlpine's Multiple Sclerosis 2005, Elsevier Churchill Livingstone, Edinburgh.
2. Erkut Z.A., Hofman M.A., Ravid R., Swaab D.F. Increased activity of hypothalamic corticotropin-releasing hormone neurons in multiple sclerosis. J. Neuroimmunol. 1995, 62:27-33.
3. Fassbender K., Schmidt R., Mossner R., Kischka U., Kuhnen J., Schwartz A., Hennerici M. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch. Neurol. 1998, 55:66-72.
4. Gold S.M., Dziobek I., Rogers K., Bayoumy A., McHugh P.F., Convit A. Hypertension and hypothalamo-pituitary-adrenal axis hyperactivity affect frontal lobe integrity. J. Clin. Endocrinol. Metab. 2005, 90:3262-3267.
5. Gold S.M., Raji A., Huitinga I., Wiedemann K., Schulz K.H., Heesen C. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J. Neuroimmunol. 2005, 165:186-191.
6. Gottschalk M., Kümpfel T., Flachenecker P., Uhr M., Trenkwalder C., Holsboer F., Weber F. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch. Neurol. 2005, 62:277-280.
7. Grasser A., Möller A., Backmund H., Yassouridis A., Holsboer F. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. Exp. Clin. Endocrinol. Diab. 1996, 104:31-37.
8. Heberden C., Meffray E., Goustard-Langelier B., Maximin E., Lavialle M. Dexamethasone inhibits the maturation of newly formed neurons and glia supplemented with polyunsaturated fatty acids. J. Steroid Biochem. Mol. Biol. 2013, 138:395-402. 10.1016/j.jsbmb.2013.07.010.
9. Heesen C., Gold S.M., Raji A., Wiedemann K., Schulz K.H. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinology 2002, 27:505-517.
10. Huitinga I., Erkut Z.A., van Beurden D., Swaab D.F. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann. Neurol. 2004, 55:37-45.
11. Kümpfel T., Then Bergh F., Pollmaecher T., Holsboer F., Trenkwalder C. Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS. Neurology 2000, 55:1231-1233.
12. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
13. Melief J., de Wit S.J., van Eden C.G., Teunissen C., Hamann J., Uitdehaag B.M., Swaab D., Huitinga I. HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. Acta Neuropathol. 2013, 126:237-249.
14. Michelson D., Stone L., Galliven E., Magiakou M.A., Chrousos G.P., Sternberg E.M., Gold P.W. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J. Clin. Endocrinol. Metab. 1994, 79:848-853.
15. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtelotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
16. Purba J.S., Raadsheer F.C., Hofman M.A., Ravid R., Polman C.H., Kamphorst W., Swaab D.F. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology 1995, 62:62-70.
17. Reder A.T., Lowy M.T., Meltzer H.Y., Antel J.P. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology 1987, 37:849-853.
18. Reder A.T., Makowiec R.L., Lowy M.T. Adrenal size is increased in multiple sclerosis. Arch. Neurol. 1994, 51:151-154.
19. Sauer J., Stalla G.K., Muller O.A., Arzt E. Inhibition of interleukin-2-mediated lymphocyte activation in patients with Cushing's syndrome: a comparison with hypocortisolemic patients. Neuroendocrinology 1994, 59:144-151.
20. Schumann E.M., Kümpfel T., Then Bergh F., Trenkwalder C., Holsboer F., Auer D.P. Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. Ann. Neurol. 2002, 51:763-767.
21. Then Bergh F., Kümpfel T., Trenkwalder C., Rupprecht R., Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999, 53:772-777.
22. Then Bergh F., Kümpfel T., Schumann E., Held U., Schwan M., Blazevic M., Wismuller A., Holsboer F., Yassouridis A., Uhr M., Weber F., Daumer M., Trenkwalder C., Auer D. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol. 2006, 6:19.
23. Then Bergh F., Kümpfel T., Yassouridis A., Lechner C., Holsboer F., Trenkwalder C. Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis. Clin. Endocrinol. (Oxf) 2007, 66:295-303.
24. Webster J.I., Tonelli L., Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 2002, 20:125-163.
25. Wei T., Lightman S.L. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997, 120:1067-1076.
26. Ysrraelit M.C., Gaitan M.I., Lopez A.S., Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008, 71:1948-1954.